Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia
Journal of Veterinary Medical Science · 2025
DOI: 10.1292/jvms.25-0193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Medical Science, 2025. Verfasst von Daiki Hirao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan. Hauptthemen laut MEDLINE: Pyridazines, Tachycardia, Supraventricular, Cardiotonic Agents, Dog Diseases. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Supraventricular tachyarrhythmia (SVTA) in dogs can cause cardiac dysfunction and may progress to heart failure. Pimobendan, an inotropic agent with calcium-sensitizing and phosphodiesterase III inhibition, is widely used in veterinary medicine. However, its influence on myocardial injury under persistent SVTA remains incompletely understood. This study aimed to evaluate whether pimobendan improves systolic function without exacerbating myocardial injury, using a canine model of rapid atrial pacing (RAP). Fourteen healthy Beagle dogs were allocated to either a control or pimobendan group. RAP was performed for three weeks at 390 bpm. Cardiac function was assessed by echocardiography before (baseline) and after RAP (3W). Concurrently, cardiac troponin I (cTnI) concentrations were measured to assess myocardial injury. In the control group, a significant increase in cTnI was observed at 3W compared with baseline (0.023 ± 0.029 ng/mL vs. 0.176 ± 0.173 ng/mL). Additionally, in the control group, echocardiographic parameters worsened, including fractional shortening (FS) (37.8 ± 4.6% vs. 24.5 ± 6.8%) and stroke volume (SV) (15.8 ± 3.1 mL vs. 10.5 ± 2.0 mL) at 3W compared with baseline. In contrast, the pimobendan group showed no significant differences in these echocardiographic parameters. cTnI concentrations also remained within the normal range without significant differences. These results suggest that pimobendan preserved systolic function without aggravating myocardial injury during sustained SVTA. Pimobendan may therefore be safe and effective cardiac inotropic agent for the treatment of dogs with SVTA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
- Animal Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
- Laboratory of Veterinary Toxicology, Cooperative Department of Veterinary Medicine, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Zitieren
APA
Hirao, D., Morita, S., Hasegewa, H., Yoshimura, A., Kawaguchi, T., Yamada, S., Oomori, T., Suzuki, K., & Fukushima, R. (2025). Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia. Journal of Veterinary Medical Science. https://doi.org/10.1292/jvms.25-0193
Vancouver
Hirao D, Morita S, Hasegewa H, Yoshimura A, Kawaguchi T, Yamada S, et al. Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia. Journal of Veterinary Medical Science. 2025. doi:10.1292/jvms.25-0193
BibTeX
@article{Hirao2025,
author = {Hirao, Daiki and Morita, Shohei and Hasegewa, Hiroshi and Yoshimura, Aritada and Kawaguchi, Takae and Yamada, Shusaku and Oomori, Takahiro and Suzuki, Kazuhiko and Fukushima, Ryuji},
title = {Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia},
journal = {Journal of Veterinary Medical Science},
year = {2025},
doi = {10.1292/jvms.25-0193}
}
EUVIMED